



Personalized Medicine Partnerships April 12, 2011 Bethesda, MD, USA

Richard Watts Senior Director Pharma Business Development

Sample & Assay Technologies



Forward-looking statements

Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics, applied testing markets and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including fluctuations from certain events including funding, budgets, and others), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, the management of intellectual property, and the integration of acquisitions of technologies and businesses. In addition certain statements contained in this news release are based on company assumptions, including, but not limited, to revenue allocations based on business segments and/or customer classes. For further information, refer to the discussion in reports that QIAGEN has filed with or furnished to the U.S. Securities and Exchange Commission (SEC).

Regulation G: The following slides contain certain summary information about QIAGEN N.V.'s sales, gross profit, operating income, net income, and earnings per share over a specific period and the comparable period, which information is presented on a "non-GAAP financial measures" basis rather than in accordance with U.S. generally accepted accounting principles (GAAP). Please review QIAGEN's press releases for information on the company's operating income, net income, and earnings per share for these periods presented on a GAAP basis. Such GAAP-basis information will also be contained in the company's reports on Form 20-F or Form 6-K to be filed with or furnished to the U.S. Securities and Exchange Commission.



QIAGEN at a glance Leading provider of sample and assay technologies

	2010	2009	Growth
Net Sales (m \$)	1,087	1,010	8%
Net Income* (m \$)	222.7	199.6	12%
EPS, adj.* (\$)	0.93	0.93	

Intellectual Property (02/11)

- >950 issued patents
- >970 pending patents
- >550 patents under license

> 500,000 Customers

- Molecular Diagnostics (hospitals, labs)
- Pharma (pharmaceutical & biotech companies)
- Academic Research (academia, research institutes)
- Applied Testing (vet., human ID, food testing, etc.)

Product Range

- >500 consumable products to collect, separate, purify, stabilize, store and amplify target analytes in samples (DNA, RNA, proteins, etc.)
- Instrumentation for above consumables
- Molecular diagnostics and research test kits

Employees

~3600 employees worldwide



* For more information on the adjusted figures, please refer to the reconciliation tables in QIAGEN's Q4 and fiscal year 2010 earnings release.



Sample Technology example Allprep FFPE DNA/RNA for extraction of both DNA and RNA from FFPE




Assay Technology example CDx assays — EGFR, KRAS, BRAF, PI3K, etc.





QIAGEN products: instruments Complete platform offering







QIAsymphony RGQ

Extensive assay menu on one system



QIAsymphony RGQ profile

- Potential to transform use of molecular diagnostics
 - Menu:
 - EU: >15 CE-marked assays, growing
 - US: developing assay menu
 - 2011: KRAS, Influenza, EBV, CMV
 - Pipeline: 12 assays
- Unprecedented flexibility
 - Fully modular expand with laboratories
 - Comprehensive cleared assays and LDTs
 - Cost-efficient flexible sample handling
- Utility and convenience
 - Wide range of starting materials (incl. FFPE)
 - Fully modular expands with the lab
 - Parallel processing up to 300 results/shift
 - Continuous loading process as available
 - Random access enables critical care



Market leadership in molecular diagnostics

QIAGEN — Leading in Molecular Diagnostics

- Proven standard in sample and assay technologies
- Unparalleled range of applications in sample technologies
- Largest MDx assay portfolio (~120 tests) & intellectual property estate
- Certified applications and systems

Four "P" Strategy in Molecular Diagnostics

Attain and expand leadership in:

- **Prevention:** screening of non-symptomatic patients to early detect diseases
- **Profiling:** testing of symptomatic patients to create or confirm diagnosis
- **Personalized Healthcare:** testing of pre-diagnosed patients to guide treatments
- **Point-of-Need:** ultra-fast and portable test systems

QIAGEN — Outlook

- High market growth of ~16%, QIAGEN among fastest growing companies in MDx ~20%
- Demand for efficiency: automation and process optimization
- Growing importance of personalized medicine, emerging point-of-need testing

QIAGEN — Benchmark in MDx



Check Status

Survival

Proliferation

PUROSEQ !

Example personalized healthcare KRAS testing in oncology

Personalized Healthcare (PHC)

- Different reactions to drugs determined by genetic make-up of patients
- Billions of dollars spent each year on ineffective or even harmful therapies
- PHC uses molecular diagnostics to developed tailored treatment strategies for individual patient groups, e.g., in metastatic colon cancer therapies
- Win–Win situation for all parties involved

QIAGEN's Portfolio for Personalized Healthcare

- MEN About 20 assays for PHC applications (e.g., KRAS, EGFR, BRAF)
 - More than 15 pharma partnerships to develop companion diagnostics (e.g., Pfizer, Amgen, Merck, AstraZeneca, BMS)
 - With KRAS testing, leading first "blockbuster" segment in PHC (~US\$100 million market potential) — established as CDx for *Erbitux* and *Vectibix*


QIAGEN — Outlook

- PHC market volume in 2008 US\$ 13 bn. with CAGR of 24% over the last decade
- Strong short- and mid-term pipeline, strong IP portfolio (e.g., PI3K)
- Cost pressures and benefits for all parties involved drive further development and dissemination

A Global Leader in Personalized Healthcare



Translational science to personalized healthcare Integrating all steps from biomarker discovery to CDx





QIAGEN's 4 "P" framework in MDx

	Laboratory-based Testing		Point of Need	
	Prevention Asymptomatic patients Goal: early detection	Profiling Symptomatic patients Goal: confirm	Personalized Healthcare Pre-diagnosed patients Goal: guide therapy	No laboratory reachable Goal: fast result, on spot
Market needs	Screening market Ultra-high throughput	Single patient testing Mid–high throughput Highest flexibility	Single patient testing Low–mid throughput Highest flexibility	Rapid turnaround Low throughput Versatile tests
Assay technologies	 Examples: HPV Chlamydia (CT) / Gonorrhoeae (NG) Trichomonas Vaginosis panel More to come 	Examples: • CMV • EBV • HBV • HIV • HCV • Influenza	Examples: • KRAS • EGFR • B-RAF • PI3K • Pathogen Genotyping	Examples: • <i>care</i> HPV • HAI • Influenza
Instruments >2010 Fully automated Fully integrated				



Known Knowns

"There are known knowns; there are things we know we know.

We also know there are known unknowns; that is to say, we know there are some things we do not know.

But there are also unknown unknowns — the ones we don't know we don't know. "

— Former United States Secretary of Defense, Donald Rumsfeld

Black Swan Theory

- The event is a surprise (to the observer)
- The event has a major impact
- After its first recording, the event is rationalized by hindsight, as if it could have been expected (e.g., the relevant data were available but not accounted for)



Predictive for Efficacy

Marker	Therapy	Clinical Utilization
HER2KRAS	Traztuzumab Panitumumab, Cetuximab	High High
BRAF	PLX-4032	High
EGFR	Gefitinib, Erlotinib	High
CCR5	Maraviroc	High
MGMT	Temazolomide	Medium
Predictive for Safety		
HLA-B5701	Abacavir	High
UGT1A1	Irinotecan	Moderate
CYP450 (2D6)	Tamoxifen	Moderate

TPMT

Sample & Assay Technologies

Moderate

6-Mercaptopurine




Personalized healthcare The 5 "P"s — good all round

Name Your

Stakeholder	Benefit
Pharma companies	Regulatory approval Competitive advantage Increase cost effectiveness of drug
Physicians	Increased safety in treatment decisions Start directly with right treatment and Save valuable time
Payers	Increase efficiency of therapies Save money in healthcare systems
Patients	Best therapy available Avoid unnecessary side effects
Providers (Dx companies, labs)	New market opportunities

But despite its obvious benefits, this has been a challenging business environment







Personalized medicine in 2011 Three major drivers







Your Name

WW acceptance: Money spent on healthcare is finite

Increased emphasis on health technology assessment (HTA) Aim: Increase cost effectiveness of treatments

Pharmaceutical companies are responding Development of companion diagnostics (CDx) Trend: to increase cost effectiveness of drugs

Scientific — Therapies to Targeted Therapies

Political — Effectiveness to Cost Effectiveness

- Advancement in understanding of disease processes lead to target drugs, more closely to specific molecular targets
- Increasing demand for diagnostic tools to identify patients with specific disease sub-types, likely to respond to the therapy
- Omic analysis becoming increasingly feasible

Regulatory — Passive to Active Regulation

- Regulatory Authorities realized benefits CDx can bring to patients
- Both EMEA and the FDA encouraging pharmaceutical companies to explore the use of CDx during drug development





The scale of the US market drives regulatory requirements FDA are setting the regulatory agenda

Regulatory oversight of therapeutics is similar across the world but the regulation of diagnostics is quite different in different territories

The FDA set the highest standards

- A CDx is considered to be a high-risk device
- New co-development guidance document to be released very soon
- Drug label must make reference to an "FDA approved and validated test"
- The expected approval route is risk based and most likely via PMA vs. 510K

Because the USA is such a significant market for drugs and diagnostics the FDA are setting the global regulatory standards

In Europe, it is significantly easier to bring a diagnostic test to market

IVD Directive is changing

Asian regulations tend to be fall somewhere between US and EU systems

Clinical validity must be shown in some local (country specific) populations




The companion diagnostic wish list —

What Pharma look for in a diagnostic partner



Key capabilities & capacities requested from Pharma



Requirement

 Assays need to be: reliable, robust, and compatible with diagnostic lab operations

- Technology, intended use and FTO
- Platform and Distribution rights


 Approval needed for the drug & the diagnostic (FDA require Dx "system" to be approved)

 Reliable & consistent quality manufacturing to ensure no restriction to access and availability

- Different models needed depending on level of drug company involvement
- Global Sales, Marketing & Distribution
- Who will pay for the test and how much?



Capabilities & capacities requested from Pharma




QIAGEN

Requirement

- Assays need to be: reliable, robust, and compatible with diagnostic lab operations
- Technology, intended use and FTO
- Platform and Distribution rights
- Approval needed for the drug & the diagnostic (FDA require Dx "system" to be approved)
- Reliable & consistent quality manufacturing to ensure no restriction to access and availability
- Different models needed depending on level of drug company involvement
- Global Sales, Marketing & Distribution
- Who will pay for the test and how much?





QIAGEN

Capabilities & capacities requested from Pharma

Regulatory

Requirement

 Approval needed for the drug & the diagnostic (FDA require Dx "system" to be approved)

- Medical Devices are regulated based upon the relative risk/benefit to the patient and classified in risk (I-III) based upon their intended use
- Most Companion Diagnostics are considered high risk, Class III devices due to clinical decisions and actions that are taken as a result of their use
- Class III devices require Pre-Market Approval (PMA)
- Diagnostic Partner must be competent in the PMA processes as well as those involved in supporting the registrational trial such as Investigational Device Exemption (IDE)
- Diagnostic Partner must also have very rigid and compliant Design Control and Quality Systems
- Diagnostic registrational capacities must match Drug registrational plans



Capabilities & capacities requested from Pharma

Commerci	al
Commerci	a

Requirement

- Different models needed depending on level of drug company involvement
- Global Sales, Marketing & Distribution

Centralized Reference Laboratory or Decentralized Pathology Labs?

- Commercial Model(s) require input:
 - □ Availability and complexity of Medical Device
 - □ Footprint of Medical Device
 - Test volume forecast
- Who needs access to the test?
 - Demographic & Geographic reach requirements
 - Sales, Service, Support
 - Promotion, Supply chain
- Price, Payors, and Reimbursement




CDx co-development partnership requirements

	Requirement	QIAGEN
Science & Technical	 Assays need to be: reliable, robust and compatible with diagnostic lab operations 	 Largest Portfolio of Research & Molecular Diagnostic technologies and platforms from sample to result
Legal, IP&L	Technology, intended use and FTOPlatform and Distribution rights	 Global Freedom To Operate & Distribute MDx portfolio and supporting workflow products
Regulatory	 Approval needed for the drug & the diagnostic (FDA require Dx "system" to be approved) 	 Global Regulatory Offices with experienced and successful personnel Portfolio of approved assays (FDA, CE, SFDA)
Availability	 Reliable & consistent quality manufacturing to ensure no restriction to access and availability 	 FDA cleared Manufacturing sites optimized for global supply of CDx under stringent Quality Systems
Commercial	 Different models needed depending on level of drug company involvement Global Sales, Marketing & Distribution 	 Direct Global Distribution, OEM / 3rd Party >2000 Global S&M, Manufacturing & Supply
Reimburse- ment	Who will pay for the test and how much?	 National Reimbursement Teams Partner to Boston Healthcare & Bridgehead Int.



CDx collaboration structures






RxDx partnership considerations Ensuring the Win–Win

Commercializing Companion Diagnostics

- Biomarker identification
- Analytical validation
- Clinical validation
- Commercialization
- Driving test adoption and clinical use
 - Biomarkers are only useful to the patients if they are ordered and used by physicians

Factors Affecting Companion Test Adoption

- Actionable result
- Access to the test
- Reimbursement
- Physician education
- Market awareness
- Acceptance of test by physicians
- Acceptance of test by patients





Plotting a course to commercialization —

QIAGEN's experiences in the development and launch of the *therascreen*[®] KRAS PCR Kit and the *therascreen*[®] EGFR PCR Kit companion diagnostics



How does the PHC market work?

Market is influenced by other stakeholders

- Patients better outcomes
- Pharma sell more drugs
- Providers spend less money

Diagnostic tests ordered by doctors

- Clinical utility
- Benefit to patients


Diagnostic tests are provided by diagnostic labs

- Major reference labs
- Smaller hospital labs
- Specialised labs

Labs can also develop their own tests (LDTs) (FOR NOW - FDA?)

Diagnostic products are supplied by diagnostic companies

- Small number of global players with complete systems
- QIAGEN





Current regulatory environment further creates a unique opportunity

Background

- Original situation with LDTs
 - □ Simple, well-understood pathology tests
 - □ Low-risk tests or those that diagnosed rare diseases and conditions
 - □ Usually used by physicians and pathologists within a single institution
 - □ No FDA approved test available
- Today
 - □ More complex LDTs
 - Often used to assess medium- to high-risk but relatively common diseases and conditions
 - □ Used to inform critical treatment, often in geographically distant commercial labs

Creation of new regulations for LDTs — FDA Guidance document expected this year

- Control of RUO product use
- Enforcement should be risk based
- Requirement for post market surveillance/reporting



Illustration of the diagnostic business model

System Placement



Harvesting Reagent Stream: Sample Prep and Assay Reagents



- Dx company places systems
- Dx company finances systems
- High sales effort
- High up-front investment

- Harvest reagent streams over long time 5 year contracts
- Reagent stream refinances instrument investment
- Low sales effort and high service effort
- Guaranteed business for years: stable cash-flow

System business is very sustainable



First to market is very rewarding Diagnostic industry runs an attractive business model

Individual labs in the Dx lab market

Success in new developing market

Very high entry barriers exist

- Contracts on closed platforms
- Not enough volume to have more suppliers

First mover creates enormous value

Saturates the market as it develops


Contracts establish long term customer business for >5 years

In saturated segments: Difficult to increase market share

Diagnostic system business: first mover advantage can establish very attractive position



Coordinating co-marketing of a drug–diagnostic with Pharma





Market adoption is influenced by many factors A true partnership approach is required

Clinical Utility

- Is the test Standard of Care?
- Existence/severity/utility of therapeutic options available
- How close is the connection between the result and patient care?
- How often is an actionable result delivered?
- Turnaround time
- Our reporting capabilities back to the client
- Availability of specialists for consult
- Ease of ordering the test

Clinical Validity & Scientific Evidence

- Supporting publications/seminal article in major journal
- Sensitivity and specificity; reproducibility, precision
- Clinically reportable range; reference intervals
- Specimen matrix, stability

Paradigm Shift?

- Economic: impact on current economics of care
- Political: physician ordering habits. Is financial reward moved from one group to another?

Regulatory Acceptance

- CPT coding
- FDA approval
- Guidance from CMS

Advocacy

- Thought leader involvement/acceptance
- Endorsement from advocacy/patient groups
- Endorsement from professional organizations

Payor Adoption

- Managed care contracts
- Edit checks on claims
- Federal government adoption
- State government adoption


Promotional Efforts

- Price
- Size and structure of the target physician specialty
- Marketing focus and effort
- Sales comprehension, focus and effort
- Partnership efforts




KRAS test adoption phases At start of the growth phase

tests ordered





Targeting the right customer by institution Key takeaways by institution type



Community Hospitals are profitability-minded, particularly if they serve as a local/regional reference lab

University Hospitals want multiple services and support but also desire efficiency as it supports their business plans

Pathology/Cytology Labs want test standardization and greater efficiency

While profit is important to **Independent Reference Labs**, increased efficiency and customer support are the key drivers

IHNs also want a breadth of services as well as automation solutions to help improve workflow and efficiency

Public Health, **VA** (Veterans Affairs Hospital Labs) and **DOD** (Department of Defense Hospital Labs) seek reliability and ease of use





Based on segmentation, important criteria for labs are:


- PMA label and approved test
- Reimbursement
- Workflow and menu
- Adoption of the new test
- Training
- Positioning
- Data to support the new test



Looking ahead —

Where now for companion diagnostics? New potential therapeutic areas to explore

Targeted therapies in oncology over the past 10 years What does the next 10 hold? PHC will surely drive CER



Source: IMS Business Review 2008

QIAGEN



Where will personalized medicine expand next...

- Disease complexity and unmet need will drive the application uptake and use of biomarkers to deliver personalised medicine where efficacy can be shown
- Multi-parameter biomarker strategies facilitate go/no-go decisions especially in complex disease scenarios:

60

50

40

20

10

0

Preclinical

- □ Imaging
- Molecular
- Protein
- Metabolite
- □ Cognitive
- Host vs. Disease
 - □ What is normal vs. what is now abnormal
 - Aberrant pathways
 - Aberrant transcription & control elements
 - Non-coding
 - MicroRNA
 - Epigenetic

Average % of company pipelines relying on biomarker data

Early clinical

(Phase I-IIa)

Source: Tufts Center for the Study of Drug Development (CSDD) 2010

Late clinical

(Phase IIb-IV)

% of pipelines with biomarker 30data



Moving away from oncology

- CDx started with Infectious Disease
 - □ Antibiotic resistance
 - □ AIDS
 - □ MDR genes (HIV & HCV)
- Oncology CDx will get increasingly complex
 - MGH Genotyping 101 mutations
 - Microarrays, deep sequencing, robustness, data, regulatory authorities, proving clinical relevance
 - Lack of standards and processes for biomarker validation
 - Challenge of co-developed drug/device technologies
 - Clinical trial design
 - Re-labelling of existing drugs with well-established pharmacogenomic variants
 - Role of post-marketing surveillance and Phase IV studies
 - Different regulatory regimes for manufactured devices and tests developed in-house
- AutoImmune (Host/Local Response)
- CNS
 - Cognition
 - Neuro
 - Pain
- Latent disease/disease prevention





Takeda Pharmaceutical Company Limited

Osaka, Japan - Janurary 11, 2011 and Durham, NC -January 10, 2011 – Takeda Pharmaceutical Company Limited and Zinfandel Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide licensing agreement regarding Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease, including potential use of the assay in combination with pioglitazone in high-risk older adults with normal cognition. Pioglitazone is the active ingredient currently marketed in Takeda's ACTOS® (pioglitazone HCI).

The TOMM40 biomarker, recently discovered by a team led by Allen Roses, M.D., Chief Executive Officer of Zinfandel, is being developed to identify individuals at high risk of developing Alzheimer's disease within the subsequent five years. Under this license agreement, Takeda and Zinfandel will attempt to prospectively validate the TOMM40 biomarker as a test of individual risk.

"There is intense interest within the medical community in identifying treatments to help delay progression or potentially prevent the onset of Alzheimer's disease, in an effort to reduce the burden of this disease," said Shigenori Ohkawa, Ph.D., Chief Scientific Officer, Takeda Pharmaceutical Company Limited. "We are energized by this partnership and the opportunity to develop an effective treatment for healthy at-risk older adults."

Under the terms of agreement, Zinfandel will receive an upfront payment of \$9 million and subsequent payments of up to \$78 million for development milestones from Takeda. Additional commercial milestones and royalties were also outlined in the agreement. Takeda will obtain an exclusive license, with the right to sublicense, develop, make, use and commercialize the TOMM40 biomarker assay, and to use the assay to identify high-risk older adults who would be candidates for clinical trials with pioglitazone to evaluate its utility.

"At Zinfandel, we have been exploring pharmacogenetics in general, and the TOMM40 biomarker specifically, to identify atrisk individuals who may be candidates for treatment in a pharmacogenetics-assisted clinical trial," said Dr. Roses. "We look forward to working with a partner like Takeda, who shares our commitment to reducing the prevalence of Alzheimer's disease over the next 20-30 years."

Alzheimer's disease is a degenerative brain disease characterized by a progressive decline in memory, thinking, comprehension, calculation, language, learning capacity and judgment sufficient to impair personal activities of daily living. Approximately 18 million people worldwide are currently suffering from Alzheimer's disease, and the rate of occurrence doubles every five years for those between 65 and 85 years of age.



- Robust science is driving partnerships in CDx
 - Regulatory policy ensures only the best is delivered
 - □ Dx partners must show experience & be able to deliver the broader picture
- Start early and start with the end in mind (Platform)
 - □ What will the Dx/Rx landscape look like at launch?
 - Who, how, where, when, and why will the test be used?
- Commercial strategies must foster the businesses goals of all stakeholders
 There are many differences
- Personalised Healthcare is now a reality
 - □ Essential for the success of next generation therapies
 - Our investment in science is delivering value through innovation most importantly; benefits for patients
- Let's work together and make a difference



For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at <u>www.qiagen.com</u> or can be requested from QIAGEN Technical Services or your local distributor.